Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04632641
Other study ID # 20-235
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 23, 2021
Est. completion date December 31, 2023

Study information

Verified date April 2024
Source Aurora Health Care
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Primary objective: To compare the safety and efficacy of closure strategies post venous access procedures. Hypothesis: We anticipate that the use of a venous closure device will decrease the time to hemostasis (TTH), time to ambulation (TTA) and time to discharge (TTD) compared to conventional methods of closure following venous access procedure.


Description:

This study will be a prospective, randomized study of patients who are undergoing one or more of the following procedures at ASLMC (Aurora St. Luke's Medical Center): Large-Bore Procedures >13 F 1. WATCHMAN® device placement 2. Atrial fibrillation/flutter/SVT (supraventricular tachycardia) ablation using cryoballoon or laser balloon 3. Leadless pacemaker 4. Pulmonary embolism thrombectomy (Inari FlowTriever system) 5. MitraClip transcatheter mitral valve repair RANDOMIZATION: Patients will be randomized into one of two venous closure groups after a clean stick has been achieved with no complications: Large-bore (14F-25F) venous access group (1:1) - Perclose ProGlide SMC - Figure 8 suture


Recruitment information / eligibility

Status Completed
Enrollment 107
Est. completion date December 31, 2023
Est. primary completion date December 31, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria: Large-bore (>13F) Venous Access Procedures Inclusion Criteria: All patients 18 years and older who are undergoing any of the following: WATCHMAN® device placement, atrial fibrillation ablation using cryoballoon or laser balloon, leadless pacemaker, Pulmonary embolism thrombectomy (Inari FlowTriever system), MitraClip transcatheter mitral valve repair at Aurora St. Luke's Medical Center from date of IRB (Institutional Review Board) approval through December 2022. All arterial line access should be radial. Exclusion criteria: Large-bore (>13F) Venous Access Procedures Exclusion Criteria: - Patients in whom introducer sheaths >25F were used in the vein during the catheterization procedure. - Patients with small femoral arteries or veins (< 5 mm in diameter). - Patients with access sites in vascular grafts. - Patients with intra-procedural bleeding around access site. Patients who cannot receive radial arterial line access. - Patients who have complications during the procedure not related to the Perclose ProGlide SMC closure device - The physician determines that they must use an alternate method as the primary venous closure method other than that which the patient was randomized to - Active systemic or cutaneous infection, or inflammation in vicinity of the groin - Pre-existing immunodeficiency disorder or chronic use of high dose systemic steroids - Known history of bleeding diathesis, coagulopathy, hypercoagulability or platelet count < 100,000 cells/mm3 - Severe co-existing morbidities with life expectancy less than 12 months - Femoral arteriotomy or femoral venotomy in < 10 days, or with any known vascular complications or residual hematoma, or with use of an intravascular closure device w/in previous 30 days - Planned femoral venous or arterial access within next 30 days - Unable to routinely walk at least 20 ft. without assistance - LMWH (low molecular weight heparin) within 8 hours before or after procedure - Pregnant and/or lactating women - Extreme morbid obesity (BMI > 40 kg/m2) or underweight (BMI < 20 kg/m2)

Study Design


Intervention

Device:
Perclose ProGlide Suture-Mediated Closure System (SMC) - LARGE-BORE PROCEDURES
The Perclose ProGlide Suture-Mediated Closure System (SMC) will be used to close the vein access site(s) at the completion of the large-bore procedure in order to achieve hemostasis.
Other:
Figure 8 Suture - LARGE-BORE PROCEDURES
A figure 8 suture will be done as a closure strategy in order to achieve hemostasis in large-bore procedures.

Locations

Country Name City State
United States Aurora St. Luke's Medical Center Milwaukee Wisconsin

Sponsors (1)

Lead Sponsor Collaborator
Aurora Health Care

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time to Achieve Hemostasis The elapsed time between "device" removal and first observed and confirmed venous hemostasis Day 1
Primary Time to Ambulate The elapsed time between removal of the final Perclose ProGlide SMC device (treatment arm) or removal of the final sheath (control arm), and the ability of subjects to stand and ambulate 20 feet without evidence of venous re-bleeding from the femoral access sites. Day 1
Secondary Time to Discharge (TTD)/Length of Stay (LOS) The elapsed time between removal of the final sheath, and the ability of subjects to be discharged. Total length of hospital stay. up to 5 days post procedure
Secondary Post Procedure Major Bleeding Bleeding associated with =2 g/dl drop in hemoglobin level requiring transfusion, bleeding that occurs at a critical site, or bleeding contributing to death. up to 30 days post procedure
Secondary Minor Bleeding Any bleeding that does not meet the criteria for major bleeding up to 30 days post procedure
Secondary Access Site Complications Access site hematoma, vascular thrombosis, vascular dissection, pseudoaneurysm, or AV (arteriovenous) fistula up to 30 days post procedure
Secondary Mortality Mortality due to vascular complications up to 30 days post procedure
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Completed NCT04571385 - A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF) Phase 2
Terminated NCT04115735 - His Bundle Recording From Subclavian Vein
Completed NCT05366803 - Women's Health Initiative Silent Atrial Fibrillation Recording Study N/A
Completed NCT02864758 - Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
Recruiting NCT05442203 - Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease N/A
Completed NCT05599308 - Evaluation of Blood Pressure Monitor With AFib Screening Feature N/A
Completed NCT03790917 - Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
Enrolling by invitation NCT05890274 - Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO N/A
Recruiting NCT05316870 - Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation N/A
Recruiting NCT05266144 - Atrial Fibrillation Patients Treated With Catheter Ablation
Not yet recruiting NCT06023784 - The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Recruiting NCT04092985 - Smart Watch iECG for the Detection of Cardiac Arrhythmias
Completed NCT04087122 - Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures N/A
Completed NCT06283654 - Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation
Recruiting NCT05416086 - iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)
Completed NCT04546763 - Study Watch AF Detection At Home
Completed NCT03761394 - Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke N/A